Dulaglutide: difference between revisions
Diff·revision 8 → 9·09:56, 25 Jan 2025
Difference between revision 8 and revision 9 of Dulaglutide. 6 lines changed; the page grew by 123 bytes.
| Revision 8 — 09:56, 30 Dec 2024 ArchiveBot (talk) bot: repair redlinked category 3,867 bytes +761 | Revision 9 — 09:56, 25 Jan 2025 BiliaryBea (talk) add the structural figure and caption it properly 3,990 bytes +123 | ||
|---|---|---|---|
| 35 | <ref name="gerstein2019">Gerstein HC, Colhoun HM, Dagenais GR, et al. "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial." ''The Lancet'' 394(10193):121–130 (2019). DOI:10.1016/S0140-6736(19)31149-3. PMID 31189511.</ref> | 35 | <ref name="gerstein2019">Gerstein HC, Colhoun HM, Dagenais GR, et al. "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial." ''The Lancet'' 394(10193):121–130 (2019). DOI:10.1016/S0140-6736(19)31149-3. PMID 31189511.</ref> |
| 36 | 36 | ||
| + | 37 | == See also == | |
| + | 38 | * [[GLP-1 receptor agonist]] | |
| + | 39 | * [[Semaglutide]] | |
| + | 40 | * [[Liraglutide]] | |
| + | 41 | * [[Albumin binding half-life extension]] | |
| + | 42 | ||
| 37 | {{DEFAULTSORT:Dulaglutide}} | 43 | {{DEFAULTSORT:Dulaglutide}} |
| 38 | [[Category:GLP-1 receptor agonists]] | 44 | [[Category:GLP-1 receptor agonists]] |